Advice
Following a resubmission:
ipilimumab (Yervoy®) is accepted for use within NHS Scotland.
Indication under review: Treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy.
Ipilimumab demonstrated a survival benefit over an investigational glycoprotein100 peptide vaccine in previously treated patients with advanced melanoma.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ipilumumab. This SMC advice is contingent upon the continuing availability of the patient access scheme or a list price that is equivalent or lower.
Download detailed advice191KB (PDF)
Medicine details
- Medicine name:
- ipilimumab (Yervoy)
- SMC ID:
- 779/12
- Indication:
- For the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 08 April 2013